Article

The Patient Care Monitor-Neutropenia Index: Development, Reliability, and Validity of a Measure for Chemotherapy-Induced Neutropenia

James P. Olsen

Scott Baldwin

Arthur C. Houts

neutropenia
ONF 2011, 38(3), 360-367. DOI: 10.1188/11.ONF.360-367

Purpose/Objectives: To provide an initial evaluation of the psychometric properties of the Patient Care Monitor 1.0 Revised-Neutropenia Index (PCM-N), a symptom-based assessment tool designed to measure health-related quality-of-life (HRQOL) changes associated with chemotherapy-induced neutropenia.

Design: Known-groups methodology and self-report instrument validation.

Setting: A large community oncology practice in Memphis, TN.

Sample: 424 patients with cancer in four samples.

Methods: All patients in the first three samples were assessed at baseline of chemotherapy administration and at a point analogous to midcycle. The fourth sample underwent a cross-sectional evaluation of the ability of the PCM-N to distinguish patients with febrile neutropenia, severe afebrile neutropenia, and no neutropenia.

Main Research Variables: PCM-N score, grade of neutropenia, and febrile status.

Findings: Internal consistency reliability and factor analysis supported the single additive scale structure of the 13 items of the PCM-N. The PCM-N demonstrated good known-groups validity and was able to distinguish patients with grades 3-4 neutropenia from those with grades 0-2. The tool also was able to distinguish patients with febrile neutropenia, severe afebrile neutropenia, and no neutropenia. Receiver operating characteristic analyses provided a psychometrically based threshold score.

Conclusions: The PCM-N is a reliable and valid instrument sensitive to changes in HRQOL associated with moderate-to-severe chemotherapy-induced neutropenia.

Implications for Nursing: Nurses can use the PCM-N as a rapid and cost-effective tool for monitoring symptoms of neutropenia in patients with cancer.

Jump to a section

    References

    Bonadonna, G., & Valagussa, P. (1981). Dose-response effect of adjuvant chemotherapy in breast cancer. New England Journal of Medicine, 304, 10-15. http://dx.doi.org/10.1056/NEJM198101013040103
    Caggiano, V., Weiss, R. V., Rickert, T. S., & Linde-Zwirble, W. T. (2005). Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103, 1916-1924. http://dx.doi.org/10.1002/cncr.20983
    Calhoun, E. A., Chih-Hung, C., Welshman, E. E., & Cella, D. (2002). A neutropenia-specific quality of life instrument: Rationale for the development of the FACT-N [Abstract 1498]. Proceedings of the American Society of Clinical Oncology, 21, 375a.
    Chang, J. (2000). Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. European Journal of Cancer, 36(Suppl. 1), S11-S14. http://dx.doi.org/10.1016/S0959-8049(99)00259-2
    Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., … Rausch, G. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine, 325, 164-170. http://dx.doi.org/10.1056/NEJM199107183250305
    Elting, L. S. (1998). Stratification in clinical trials of febrile neutropenia. Supportive Care in Cancer, 6, 457-461. http://dx.doi.org/10.1007/s005200050194
    Fortner, B. V., Baldwin, S., Schwartzberg, L., & Houts, A. C. (2006). Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. Journal of Pain and Symptom Management, 31, 207-214. http://dx.doi.org/10.1016/j.jpainsymman.2005.07.009
    Fortner, B. V., Durrence, H. H., Mao, Q., Schwartzberg, L. S., & Houts, A. C. (2002, December). Development, reliability, and validity of the Cancer Care Monitor Neutropenia Index (CCM-N). Paper presented at the annual meeting of the American Society of Hematology, Philadelphia, PA.
    Fortner, B. V., & Houts, A. C. (2006). Greater physical and psychological symptom burden in patients with grade 3/4 chemotherapy-induced neutropenia. Supportive Cancer Therapy, 3, 173-177. http://dx.doi.org/10.3816/SCT.2006.n.015
    Fortner, B. V., Houts, A. C., & Schwartzberg, L. (2006). A prospective investigation of chemotherapy-induced neutropenia and quality of life. Journal of Supportive Oncology, 4, 472-478.
    Fortner, B. V., Okon, T., Schwartzberg, L., Tauer, K., & Houts, A. C. (2003). The Cancer Care Monitor: Psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. Journal of Pain and Symptom Management, 26, 1077-1092. http://dx.doi.org/10.1016/j.jpainsymman.2003.04.003
    Fortner, B. V., Schwartzberg, L., Tauer, K., Houts, A. C., Hackett, J., & Stolshek, B. S. (2005). Impact of chemotherapy-induced neutropenia on quality of life: A prospective pilot investigation. Supportive Care in Cancer, 13, 522-528. http://dx.doi.org/10.1007/s00520-004-0757-4
    Fortner, B. V., Stolshek, B., Durrence, H. H., Taylor, D. J., Okon, T., Schwartzberg, L., … Houts, A. C. (2002, March). Quality of life changes during the first cycle of myelosuppressive chemotherapy. Paper presented at the Assessing Clinical Significance for QoL Measures in Oncology Research: State-of-the-Science Symposium, Rochester, MN.
    Fortner, B. V., Stolshek, B. S., Tauer, K. W., Okon, T. A., Durrence, H. H., White, J., … Schwartzberg, L. (2002). Chemotherapy-induced neutropenia (CIN) is associated with lower quality of life (QOL) in patients with cancer [Abstract 640]. Annals of Oncology, 13(Suppl. 5), 174.
    Fortner, B. V., Tauer, K. W., Okon, T., Houts, A. C., & Schwartzberg, L. S. (2005). Experiencing neutropenia: Quality-of-life interviews with adult cancer patients. BMC Nursing, 4, 4-12. http://dx.doi.org/10.1186/1472-6955-4-4
    Glaspy, J., Hackett, J., Flyer, P., Dunford, D., & Liang, B. (2001). Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities [Abstract 1812]. Blood, 98, 432a.
    National Cancer Institute Cancer Therapy Evaluation Program. (2003a). Common Terminology Criteria for Adverse Events [v3.0]. Washington, DC: Author.
    National Cancer Institute Cancer Therapy Evaluation Program. (2003b). Common Toxicity Criteria [v2.0]. Washington, DC: Author.
    Nirenberg, A., Bush, A. P., Davis, A., Friese, C. R., Gillespie, T. W., & Rice, R. D. (2006a). Neutropenia: State of the knowledge part I. Oncology Nursing Forum, 33, 1193-1201. http://dx.doi.org/10.1188/06.ONF.1193-1201
    Nirenberg, A., Bush, A. P., Davis, A., Friese, C. R., Gillespie, T. W., & Rice, R. D. (2006b). Neutropenia: State of the knowledge part II. Oncology Nursing Forum, 33, 1202-1208. http://dx.doi.org/10.1188/06.ONF.1202-1208
    Padilla, G., & Ropka, M. E. (2005). Quality of life and chemotherapy-induced neutropenia. Cancer Nursing, 28, 167-171. http://dx.doi.org/10.1097/00002820-200505000-00001
    Pettengell, R., Gurney, H., Radford, J. A., Deakin, D. P., James, R., Wilkinson, P. M., … Crowther, D. (1992). Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood, 80, 1430-1436.
    Ropka, M. E., & Padilla, G. (2007). Assessment of neutropenia-related quality of life in a clinical setting. Oncology Nursing Forum, 34, 403-409. http://dx.doi.org/10.1188/07.ONF.403-409
    Wagner, L. I., Beaumont, J. L., Ding, B., Malin, J., Peterman, A., Calhoun, E., & Cella, D. (2008). Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: Validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N). Supportive Care in Cancer, 16, 47-56. http://dx.doi.org/10.1007/s00520-007-0270-7